Efficacy of China-produced Camrelizumab with Apatinib for First-line Treatment in Middle and Advanced Stages of Primary Liver Cancer

Efficacy of China-produced Camrelizumab with Apatinib for First-line Treatment in Middle and Advanced Stages of Primary Liver Cancer

Background Targeted therapies and immunotherapies, represented by programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have demonstrated high efficacies in multiple cancers. China-produced PD-1/PD-L1 inhibitors have been approved for use recently. Objective T...

Full description

Bibliographic Details
Main Author: Jinfa XU, Wencan SONG, Zhongxian ZHENG, Yu BAO, Gaoyan HUA, Qing CAI, Weiwei SHI, Xiufang ZHANG, Jianhua ZHANG, Zhou TONG, Guoan XIA, Fei LIU, Lintao LIU, Kesheng XIAO
Format: Article
Language:zho
Published: Chinese General Practice Publishing House Co., Ltd 2022-09-01
Series:Zhongguo quanke yixue
Subjects:
liver neoplasms|programmed cell death 1 receptor|immune checkpoint inhibitors|camrelizumab|apatinib|treatment outcome
Online Access:https://www.chinagp.net/fileup/1007-9572/PDF/zx20220208.pdf

Internet

https://www.chinagp.net/fileup/1007-9572/PDF/zx20220208.pdf

Similar Items